Endocrine Pathology

, Volume 28, Issue 2, pp 121–127 | Cite as

Neuroendocrine Tumors of the Breast

  • Daniel W. Visscher
  • Saba Yasir


A small but increasingly recognized and studied subset of breast carcinomas are characterized by neuroendocrine (NE) differentiation. As with nearly all forms of breast neoplasia, NE tumors are characterized by considerable heterogeneity in microscopic appearance and clinical aggressiveness. About half of NE breast carcinomas recapitulate the histological spectrum typical of their counterparts in other organ systems, varying from “carcinoid-like” to small cell carcinoma, with most representing intermediate grade tumors. Despite NE morphology, these tumors have a high frequency of estrogen receptor expression. Clinical outcomes of women with NE breast carcinomas are reliably grade and stage dependent. Tumors associated with “solid papillary” differentiation comprise the remaining cases of NE breast neoplasia. Solid papillary carcinoma is an intrinsically low grade/favorable prognosis class of breast neoplasia that usually presents in post-menopausal age groups. About half of solid papillary carcinoma present as a distinctive pattern of ductal carcinoma in situ that may be difficult to recognize owing to its close resemblance to florid proliferative lesions. Invasive solid papillary carcinomas are characterized by a variety of histological patterns and often show mucinous differentiation. Future studies are necessary to better define the histogenesis, optimal classification, and improved directed therapies for NE breast neoplasia.


Breast carcinoma Neuroendocrine carcinoma Solid papillary carcinoma 


  1. 1.
    Lakhani SR, Ellis IO, Schnitt SJ, et al. WHO Classification of Tumours of the Breast. Lyon: IARC Press, 2012.Google Scholar
  2. 2.
    Cubilia AL, Woodruff JM. Primary carcinoid tumors of the breast: a report of 8 cases. Am J Surg Pathol 1977 1: 283–292.CrossRefGoogle Scholar
  3. 3.
    Capella C, Eusebi V, Mann B Endocrine differentiation in mucoid carcinoma of the breast. Histopathology 1980 4: 513–630CrossRefGoogle Scholar
  4. 4.
    Sapino A, Righi L, Cassoni P, Papotti M, Gugliotta P, Bussolati G expression of apocrine differentiation markers in neuroendocrine breast carcinomas of aged women Mod Pathol 2001 14(8): 768–776.CrossRefPubMedGoogle Scholar
  5. 5.
    Mohanty SK, Kim SA, DeLair DF, Bose S, Laury AR, Chopra S, Mertens RB, Dhall D. Comparison of metastatic neuroendocrine neoplasms to the breast and primary invasive mammary carcinomas with neuroendocrine differentiation Mod Pathol 2016 28, 788–798.CrossRefGoogle Scholar
  6. 6.
    Tang F, Wei B, Tian Z, Gilcrease MZ, Huo L, Albarracin CT, Resetkova E, Zhang H, Sahin A, Chen J, Bu H, Abraham S, Wu Y Invasive mammary carcinoma with neuroendocrine differentiation: histological features and diagnostic challenges Histopathology 2011 59: 1050115.CrossRefGoogle Scholar
  7. 7.
    Tian Z, Wei B, Tang F, Wei W, Gilcrease MZ, Huo L, Albarracin CT, Resetkova E, Middleton L, Sahin A, Xing Y, Hunt K, Chen J, Bu H, Rashid A, Abraham S, Wu Y Prognostic significance of tumor grading and staging in mammary carcinomas with neuroendocrine differentiation Hum Pathol 2011 42: 1169–1177.CrossRefPubMedGoogle Scholar
  8. 8.
    Wei B, Ding T, Xing Y, Wei W, Tian Z, Tang F, Abraham S, Nayeemuddin K, Hunt K, Wu Y Invasive neuroendocrine carcinoma of the breast –a distinct subtype of aggressive mammary carcinoma. Cancer 2010 116: 4463–4473.CrossRefPubMedGoogle Scholar
  9. 9.
    Cloyd JM, Yang RL, Allison KH. Impact of histological subtype on long-term outcomes of neuroendocrine carcinoma of the breast. Breast Cancer Res Treat. 2014; 148: 637–644.CrossRefPubMedGoogle Scholar
  10. 10.
    Lopez-Bonet E, Alonso-Ruano M, Barraza G, Vazquez-Martin A, Bernando L, Menendez JA Solid neuroendocrine breast carcinomas: incidence, clinico-pathological features and immunohistochemical profiling Oncology Reports 2008 20: 1369–1374.PubMedGoogle Scholar
  11. 11.
    Shin S, DeLellis R, Ying L, Rosen PP Small cell carcinoma of the breast—a clinicopathologic and immunohistochemical study of new patients Am J Surg Pathol 2000 24(9): 1231–1238CrossRefPubMedGoogle Scholar
  12. 12.
    Rabban JT, Koerner FC, Lerwill MF Solid papillary ductal carcinoma in situ versus usual ductal hyperplasia of the breast: a potentially difficult distinction resolved by cytokeratin 5/6. Hum Pathol 2006 37: 787–793.CrossRefPubMedGoogle Scholar
  13. 13.
    Tan BY, Thike AA, Ellis IO, Tan PH Clinicopathologic characteristics of solid papillary carcinoma of the breast Am J Surg Pathol 2016 40: 1334–1342.CrossRefPubMedGoogle Scholar
  14. 14.
    Nassar H, Qureshi H, Adsay NV. Clinicopathologic analysis of solid papillary carcinoma of the breast and associated invasive carcinoma. Am J Surg Pathol. 2006; 30: 501–507.CrossRefPubMedGoogle Scholar
  15. 15.
    Kwon SY, Bae YK, Gu MJ Neuroendocrine differentiation correlates with hormone receptor expression and decreased survival in patients with invasive breast carcinoma. Histopathology 2014; 64: 647–659.CrossRefPubMedGoogle Scholar
  16. 16.
    Bogina G, Munari E, Brunelli M. Neuroendocrine differentiation in breast carcinoma: clinicopathological features and outcome. Histopathology 2015; 68: 422–432.CrossRefPubMedGoogle Scholar
  17. 17.
    Weigelt B, Geyer FC, Horlings HM et al Mucinous and neuroendocrine breast carcinomas are transcriptionally distinct from invasive ductal carcinomas of no special type. Mod Pathol. 2009; 22:1401–1414.CrossRefPubMedGoogle Scholar
  18. 18.
    Marchio C, Geyer FC, Ng CK, Piscuiglio S, De Filippo MR, Cupo M, Schultheis AM, Lim RS, Burke KA, Guerini-Rocco E, Papotti M, Norton L, Sapino A, Weigelt B, Reis-Filho JS. The genetic landscape of breast carcinomas with neuroendocrine differention. J Pathol 2016;  10.1002/path.4837.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2017

Authors and Affiliations

  1. 1.Mayo ClinicRochesterUSA

Personalised recommendations